ROBERT S JANSSEN
Medical Practice in Atlanta, GA
License number
Pennsylvania MD023379E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Atlanta, GA 30329
Pennsylvania
Pennsylvania
Personal information
See more information about ROBERT S JANSSEN at radaris.comName
Address
Phone
3838 Henry Ct, Duluth, GA 30096
402 Union Hill Church Rd, Gordon, GA 31031
318 W Church St, Villa Rica, GA 30180
1364 Rainier Falls Dr NE, Atlanta, GA 30329
2845 Abbottswell Dr, Alpharetta, GA 30022
Professional information
Inhibition Of Hiv Infection Fhrough Chemoprophyalxis
US Patent:
2007026, Nov 15, 2007
Filed:
Jan 31, 2007
Appl. No.:
11/669547
Inventors:
Walid Heneine - Atlanta GA, US
Thomas Folks - Snellville GA, US
Robert Janssen - Atlanta GA, US
Ronald Otten - Villa Rica GA, US
J. Garcia-Lerma - Decatur GA, US
Thomas Folks - Snellville GA, US
Robert Janssen - Atlanta GA, US
Ronald Otten - Villa Rica GA, US
J. Garcia-Lerma - Decatur GA, US
International Classification:
A61K 31/52, A61K 31/505, A61K 31/675, A61P 31/18
US Classification:
514081000, 514263100, 514263400, 514274000
Abstract:
A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.